Anti-Human CD274 Recombinant Antibody (B60-55) (CAT#: TAB-0997CL)

Figure 1 Specific binding of mAb B60-55 for human or cynomolgus PD-L1.

Binding activity of mAb B60-55 to hPD-L1 protein by ELISA.

Luan, Y., Chai, D., Peng, J., Ma, S., Wang, M., Ma, H., ... & Qin, S. (2016). A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. International immunopharmacology, 31, 248-256.

Figure 2 Figure 2 Specific binding of mAb B60-55 for human or cynomolgus PD-L1.

The binding of mAb B60-55 to hPD-L1 protein expressing in HEK293 cells compared with HEK293 cell not express certain proteins; The data shown as statistical analysis of the mean fluorescence intensity in various group.

Luan, Y., Chai, D., Peng, J., Ma, S., Wang, M., Ma, H., ... & Qin, S. (2016). A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. International immunopharmacology, 31, 248-256.

Figure 3 Specific binding of mAb B60-55 for human or cynomolgus PD-L1.

The binding of mAb B60-55 to hB7H3 protein expressing in HEK293 cells compared with HEK293 cell not express certain proteins; The data shown as statistical analysis of the mean fluorescence intensity in various group.

Luan, Y., Chai, D., Peng, J., Ma, S., Wang, M., Ma, H., ... & Qin, S. (2016). A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. International immunopharmacology, 31, 248-256.

Figure 4 Specific binding of mAb B60-55 for human or cynomolgus PD-L1.

The binding of mAb B60-55 to hPD-L2 protein expressing in HEK293 cells compared with HEK293 cell not express certain proteins; The data shown as statistical analysis of the mean fluorescence intensity in various group.

Luan, Y., Chai, D., Peng, J., Ma, S., Wang, M., Ma, H., ... & Qin, S. (2016). A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. International immunopharmacology, 31, 248-256.

Figure 5 Specific binding of mAb B60-55 for human or cynomolgus PD-L1.

The binding of mAb B60-55 to mPD-L1 protein expressing in HEK293 cells compared with HEK293 cell not express certain proteins; The data shown as statistical analysis of the mean fluorescence intensity in various group.

Luan, Y., Chai, D., Peng, J., Ma, S., Wang, M., Ma, H., ... & Qin, S. (2016). A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. International immunopharmacology, 31, 248-256.

Figure 6 Specific binding of mAb B60-55 for human or cynomolgus PD-L1.

The binding of mAb B60-55 to cPD-L1 protein expressing in HEK293 cells compared with HEK293 cell not express certain proteins; The data shown as statistical analysis of the mean fluorescence intensity in various group.

Luan, Y., Chai, D., Peng, J., Ma, S., Wang, M., Ma, H., ... & Qin, S. (2016). A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. International immunopharmacology, 31, 248-256.

Figure 7 B60-55 mAb competitively bind to PD-L1 with PD1. Competitive ELISA.

Binding activity of mAb B60-55 to PD-L1 previously immobilized on ELISA plates in the presence of certain amount of PD1.

Luan, Y., Chai, D., Peng, J., Ma, S., Wang, M., Ma, H., ... & Qin, S. (2016). A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. International immunopharmacology, 31, 248-256.

Figure 8 B60-55 mAb competitively bind to PD-L1 with CD80. Competitive ELISA.

Binding activity of mAb B60-55 to PD-L1 previously immobilized on ELISA plates in the presence of certain amount of CD80.

Luan, Y., Chai, D., Peng, J., Ma, S., Wang, M., Ma, H., ... & Qin, S. (2016). A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. International immunopharmacology, 31, 248-256.

Figure 9 B60-55 mAb overcomes PD-L1-mediated inhibition of T-cell activation.

Activation effects of anti-PD-L1 mAbs on PBMCs. Isolated PBMCs were added to 96-well flat-bottomed tissue culture plates at 2 × 105 cells/well activated by anti-CD3 (1 μg/ml) and anti-CD28 (0.2 μg/ml) in the presence of 2 μg/ml mAb B60-55 or isotype control antibody. Plates were cultured at 37 °C in a humidified incubator with 5% CO2 for five days. The levels of IFN-γ were measured by ELISA assay.

Luan, Y., Chai, D., Peng, J., Ma, S., Wang, M., Ma, H., ... & Qin, S. (2016). A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. International immunopharmacology, 31, 248-256.

Figure 10 B60-55 mAb overcomes PD-L1-mediated inhibition of T-cell activation.

Anti-PD-L1 mAb B60-55 enhanced the activation of CD4+ T cells in a dendritic cell-T cell mixed lymphocyte assay. The EC50 of mAb B60-55 for IFN-γ levels on dendritic cell-T cell mixed lymphocyte assay was 0.189 μg/ml.

Luan, Y., Chai, D., Peng, J., Ma, S., Wang, M., Ma, H., ... & Qin, S. (2016). A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. International immunopharmacology, 31, 248-256.

Figure 11 B60-55 mAb overcomes PD-L1-mediated inhibition of T-cell activation.

The expression of PDL1 and HLA-DR on dendritic cell-T cell were detected by flow cytometry.

Luan, Y., Chai, D., Peng, J., Ma, S., Wang, M., Ma, H., ... & Qin, S. (2016). A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. International immunopharmacology, 31, 248-256.

Figure 12 Therapeutic effect of anti-PD-L1 antibodies in mouse tumor models.

A375/PBMCs (5:1) mixed cells were inoculated s.c. into the right flank of female NOD/SCID mice. Treatment with anti-PD-L1 antibodies (BII 61-62, B60-55 and MEDI4736) or isotype control was initiated on day 0 at 3 mg/kg, and continued with another 3 doses once per week by i.p. injection.

Luan, Y., Chai, D., Peng, J., Ma, S., Wang, M., Ma, H., ... & Qin, S. (2016). A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. International immunopharmacology, 31, 248-256.

Figure 13 Preliminary PK study in cynomolgus monkey.

The B60-55 mAb serum concentration versus time profiles for 6 mg/kg doses in one male cynomolgus monkey.

Luan, Y., Chai, D., Peng, J., Ma, S., Wang, M., Ma, H., ... & Qin, S. (2016). A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. International immunopharmacology, 31, 248-256.